Je selectiemandje is leeg.
Maak een selectie van ETF's die je wilt vergelijken.
Voeg een ETF toe door op "Vergelijk" te klikken op een ETF-profiel of door een ETF aan te vinken in de ETF-zoekfunctie.
Moderna, Inc.
ISIN US60770K1079
|WKN A2N9D9
Marktkapitalisatie (in EUR)
15,976 m
Land
United States
Sector
Healthcare
Dividendrendement
0.00%
Overzicht
Koers
Beschrijving
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Grafiek
Financiële kerngegevens
Kerncijfers
| Marktkapitalisatie, EUR | 15,976 m |
| WPA, EUR | -6.43 |
| KBV | 2.2 |
| K/W | 27.9 |
| Dividendrendement | 0.00% |
Winst- en verliesrekening (2025)
| Omzet, EUR | 1,723 m |
| Netto-inkomen, EUR | -2,501 m |
| Winstmarge | -145.16% |
In welke ETF zit Moderna, Inc.?
Er zijn 19 ETF's die Moderna, Inc. bevatten. Al deze ETF's staan in de tabel hieronder. De ETF met de grootste weging van Moderna, Inc. is de iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
Prestaties
Rendementsoverzicht
| YTD | +52,05% |
| 1 maand | -6,32% |
| 3 maanden | +6,44% |
| 6 maanden | +84,71% |
| 1 jaar | +67,73% |
| 3 jaar | -66,54% |
| 5 jaar | -72,71% |
| Since inception | +149,94% |
| 2025 | -31,22% |
| 2024 | -57,11% |
| 2023 | -45,95% |
| 2022 | -23,33% |
Maandelijks rendement in een heat map
Risico
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risico-overzicht
| Volatiliteit 1 jaar | 62,79% |
| Volatiliteit 3 jaar | 60,34% |
| Volatiliteit 5 jaar | 64,40% |
| Rendement/Risico 1 jaar | 1,08 |
| Rendement/Risico 3 jaar | -0,51 |
| Rendement/Risico 5 jaar | -0,35 |
| Maximaal waardedaling 1 jaar | -31,68% |
| Maximaal waardedaling 3 jaar | -86,93% |
| Maximaal waardedaling 5 jaar | -95,12% |
| Maximaal waardedaling sinds aanvang | -95,12% |
Voortschrijdende volatiliteit over 1 jaar
Nieuwste artikelen
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.
Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.